MARKET

REPH

REPH

Recro Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.050
-0.070
-3.30%
Closed 16:00 09/24 EDT
OPEN
2.130
PREV CLOSE
2.120
HIGH
2.130
LOW
2.040
VOLUME
121.65K
TURNOVER
--
52 WEEK HIGH
5.29
52 WEEK LOW
1.490
MARKET CAP
95.36M
P/E (TTM)
-2.6808
1D
5D
1M
3M
1Y
5Y
Here’s Why Taking Profits in Recro Pharma (REPH) Resulted to a Great Outcome for Artko Capital
Artko Capital LP, an investment management firm, published its second-quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.5% was delivered by the fund for the second quarter of 2021, underperforming the S&P 500 Index, the R...
Insider Monkey · 2d ago
Recro Signs Renewable Energy Agreement With Georgia Power
Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic
Benzinga · 5d ago
Recro Pharma Signs Agreement to Purchase Renewable Energy Credits From Georgia Power
MT Newswires · 5d ago
Recro Pharma's Return On Capital Employed Overview
According to Benzinga Pro, during Q2, Recro Pharma (NASDAQ:REPH) earned $1.84 million, a 164.34% increase from the preceding quarter. Recro Pharma also posted a total of $18.02 million in sales, a 7.22% increase since Q1.
Benzinga · 09/16 15:36
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
Zacks.com · 09/16 07:46
BRIEF-Recro Pharma Inc Files Prospectus Relates To Resale Of Up To 9.3 Million Shares
reuters.com · 09/10 21:10
BRIEF-Recro And Biocorrx Expand Development And Manufacturing Relationship To Support Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
reuters.com · 09/08 11:33
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and BioCorRx, Inc. (...
GlobeNewswire · 09/08 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REPH. Analyze the recent business situations of Recro Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REPH stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 36.35M
% Owned: 78.14%
Shares Outstanding: 46.52M
TypeInstitutionsShares
Increased
20
10.99M
New
16
4.86M
Decreased
27
2.49M
Sold Out
21
941.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Independent Director
Wayne Weisman
President/Chief Executive Officer/Director
J. David Enloe
Chief Financial Officer
Ryan Lake
Director
Geraldine Henwood
Independent Director
William Ashton
Independent Director
Michael Berelowitz
Independent Director
Winston Churchill
Independent Director
James Miller
Independent Director
Laura Parks
Independent Director
Bryan Reasons
No Data
About REPH
Recro Pharma, Inc. is a contract development and manufacturing organization (CDMO). The Company is engaged in solving formulation and manufacturing challenges for companies developing oral solid dose drug products. It also focuses on developing sterile injectables oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. It operates in one segment. It provides support services capabilities, which includes preparation of clinical trial supplies, specialized services for the development and Good Manufacturing Practices (GMP) of products, as well as aseptic fill/finish and lyophilization. The Company develops and/or manufactures various products, such as Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM and Verapamil SR. Its manufacturing and development capabilities include formulation, product development through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms.

Webull offers kinds of Recro Pharma Inc stock information, including NASDAQ:REPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REPH stock methods without spending real money on the virtual paper trading platform.